Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib Combined With Chemotherapy in Newly Diagnosed Ph+ ALL
NCT06051409Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of olverembatinib in acute lymphoblastic leukemia (ALL), sponsored by Ascentage Pharma. Started Aug 2023; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06051409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051409.